Atom Investors’s ALX Oncology ALXO Stock Holding History

Atom Investors’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,477	Closed	-$333K	–	193
2021 Q4	$333K	Buy	+15,477	New	+$668K	0.06%	191

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Atom Investors's ALXO Position: Q1 2022 in Review

Atom Investors sold out of ALX Oncology (ALXO) in Q1 2022, closing a stake of 15,477 shares — an estimated $333K sold.

Atom Investors first reported a position in ALXO in Q4 2021 and held it in 1 quarter. The position peaked at $333K in Q4 2021. 96 funds tracked by Wall St. Rank hold ALXO as of Q1 2022.

Atom Investors reported no remaining ALX Oncology position as of Q1 2022 after selling out during the quarter.
Atom Investors sold 15,477 ALX Oncology shares in Q1 2022, an estimated $333K.
Atom Investors first reported a position in ALX Oncology in Q4 2021 and held it in 1 quarter.
Atom Investors's ALX Oncology position peaked at $333K in Q4 2021.
96 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2022.

Based on Atom Investors's 13F filing for Q1 2022, filed 16 May 2022.